Physician profile
Skantha Manjunath
NPI 1447464458
$5,226.47
in general payments reported to CMS, 2019-2025
30 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.58 · 2020: $119 · 2021: $365 · 2022: $428 · 2023: $1,582 · 2024: $1,465 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,170.33 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,357.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $691.58 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Electromed, INC. | $551.73 | 2023-2025 | Smartvest |
| Inspire Medical Systems, INC. | $347.30 | 2023-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $319.86 | 2023-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.68 | 2019-2023 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $242.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $215.44 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $154.18 | 2020-2024 | Yupelri |
| Shionogi INC | $148.81 | 2021-2023 | Fetroja |
| Paratek Pharmaceuticals, INC. | $130.29 | 2023-2025 | Nuzyra |
| Insmed, INC. | $123.49 | 2024-2025 | Arikayce |
| Baxter Healthcare | $100.51 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $82.98 | 2023-2024 | |
| Harmony Biosciences LLC | $82.37 | 2023-2025 | Wakix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $57.34 | 2025 | Yupelri |
| Amgen INC. | $46.04 | 2024-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $43.20 | 2023 | Acthar |
| Pfizer INC. | $36.43 | 2021 | |
| United Therapeutics Corporation | $33.29 | 2025 | Tyvaso |
| Philips North America LLC | $31.22 | 2020-2025 | Home Pi Undivided |
| Takeda Pharmaceuticals U.S.A., INC. | $29.96 | 2020-2021 | |
| 3b Medical, INC. | $29.45 | 2024 | Luna |
| Merck Sharp & Dohme LLC | $28.28 | 2022-2023 | |
| Lilly USA, LLC | $22.25 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $18.42 | 2021 | |
| Resmed Corp | $15.85 | 2023 | |
| Zoll Respicardia, INC. | $15.37 | 2024 | Remede System |
| Gilead Sciences, INC. | $14.52 | 2023 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skantha Manjunath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.